Struggling blood disorder biotech shuts down via reverse merger


Imara Inc., the blood disorder-focused company that earlier this year cut its staff to just six people, will be no more following a reverse merger with a Colorado biotech.

Previous MacroGenics strikes deal with Gilead potentially worth more than $1.7B
Next Tickets available to 2022 Health Care Heroes awards event